Introduction: There is insufficient evidence regarding the appropriate dose of methotrexate (MTX) required to achieve specific treatment goals in patients with rheumatoid arthritis (RA) receiving biologic drugs in Japan. The present study aimed to assess the dose-response effect of MTX in combination with adalimumab (ADA) to achieve low disease activity (LDA) and/or remission at 24 weeks in RA patients. Methods: This analysis used data of the ADA all-case survey in Japan (n = 7740), and 5494 patients who received ADA and MTX were classified into five groups by weighted average MTX dose ([0-\4, 4-\6, 6-\8, 8-\10, and C10 mg/week). Of the 5494 patients, 3097 with baseline 28-joint disease activity score based on erythrocyte sedimentation rate [3.2 were analyzed for effectiveness by MTX dose. Results: In biologic-naïve patients (n = 1996/ 3097), LDA/remission rates increased with MTX up to 6-\8 mg/week and then plateaued at Electronic supplementary material The online version of this article (
INTRODUCTION
Adalimumab (ADA; Humira Ò , AbbVie Inc., North Chicago, IL, USA), a fully human monoclonal antibody to tumor necrosis factor-a, was approved in Japan in 2008 for the treatment of rheumatoid arthritis (RA) [1] [2] [3] [4] . The safety and effectiveness of ADA has been confirmed with the results of an all-case postmarketing surveillance study that enrolled 7740 Japanese patients with RA (ClinicalTrials.gov identifier, NCT01076959) [5, 6] . Methotrexate (MTX) was approved in Japan in 1999 for the treatment of RA at the dose of B8 mg/week, and higher doses up to 16 mg/week, which is lower than the maximum weekly dose in Western countries, were additionally approved in 2011 [7] . Clinical studies conducted in and outside of Japan have shown that the combination of ADA and MTX is more effective than monotherapy with either drug [8] [9] [10] [11] [12] . In fact, the 2013 updates of the EULAR recommendations for the management of RA with synthetic and biological disease-modifying antirheumatic drugs describe that biological disease-modifying antirheumatic drugs (DMARDs) should be used preferentially in combination with MTX or other conventional synthetic DMARDs [8] . However, evidence is lacking in terms of the optimal dose of MTX used in combination with TNF inhibitors. While the CONCERTO trial (ClinicalTrials.gov identifier, NCT01185301) [11] has described the dose-response profile of MTX in bio-naïve patients with early stage RA, no studies have reported the corresponding data in patients with established RA in the clinical setting. In the present (MELODY) study, we conducted an analysis of data from the all-case postmarketing surveillance of ADA in 7740 Japanese patients with RA [6] by stratifying patients according to the clinical MTX dosages used in order to evaluate the effects of MTX dose in patients receiving ADA. Patients were classified as biologic-naïve and biologic-exposed patients, and the effects of MTX dose on the rates of achievement of low disease activity (LDA) and remission as determined by 28-joint Disease Activity Score (DAS28) as efficacy measures were analyzed using the maximum-contrast method
METHODS
In the MELODY study, we conducted secondary analyses of central registry data from an all-case postmarketing surveillance study with follow-up periods of 24 weeks for efficacy and 28 weeks for safety [6] . These analyses had been requested by the Ministry biologic-naïve and biologic-exposed patients. Prior biologic treatment was determined to be a significant factor (p\0.0001) in the multivariate logistic analysis.
Safety Evaluation
For safety evaluation, all adverse events (AEs) were recorded and tabulated based on preferred terms from the Medical Dictionary for Regulatory Activities, version 14.0 [14] . The The safety analysis for the MELODY study was performed with 5494 of the 7740 patients registered in the all-case postmarketing surveillance study [6] : specifically, all patients except the 2241 patients who did not use MTX concomitantly with ADA and the five patients for whom the MTX dosage was unspecified. The safety endpoints were the incidences of ADRs, serious ADRs, infections, and serious infections.
Multiplicity was not considered in the contrast test and Cox regression analysis, as this study was an explanatory study. All tests were two-sided and p\0.05 was defined as significant, except for interactions (p\0.10).
All statistical analyses were performed with SAS 9.3 (SAS Institute, Cary, NC, USA). This article does not contain any new studies with human subjects performed by any of the authors.
RESULTS
In this post hoc analysis of the all-case survey with ADA, patients were stratified only by previous use of biologics to assess the effect of MTX dose on patients receiving ADA after the following analysis: In the selected model (n = 3097; Akaike's information criterion, 3587.7), the essential variables were previous use of biologics (p\0.0001), baseline DAS28-ESR (p\0.0001), age (p = 0.0013), Steinbrocker class (p = 0.0004), diabetes mellitus (p = 0.0206), sex (p = 0.0068), group (p = 0.0280), and interaction between age and diabetes mellitus (p = 0.0558) (Data on file, AbbVie GK, Tokyo, Japan). Although both previous use of biologics and baseline DAS28-ESR showed a highly significant effect on the dose-response profile of MTX, baseline DAS28-ESR did not differ by MTX dose.
In the 1996 biologic-naïve patients, there were significant differences among the five MTX dose groups with respect to sex, age, disease duration, renal comorbidities, and percentages in each Steinbrocker stage at baseline. In the 1101 biologic-exposed patients, there were significant differences among the five MTX dose groups with respect to respiratory comorbidities, pulmonary disease history or comorbidity, and percentages in each Steinbrocker class (Tables 1,  2) . Mean DAS28-ESR scores at baseline did not differ by MTX dose in either patient population, and both populations had similar scores (Tables 1,   2 ).
LDA and remission rates at week 24 are summarized in Fig. 1 . In the 1996 biologic-naïve patients, LDA rates were 39.2, 43.0, 49.7, 49.8, and 50.5% in groups 1 through 5, respectively ( Fig. 1A, left ), and remission rates were 19.6, 19.0, 28.4, 26.5, and 29.2%, respectively (Fig. 1B, left) . There was a tendency toward a dose-dependent increase in both LDA and remission rates among groups 1, 2, and 3; however, the rates did not increase further in groups 4 and 5. A contrast test adjusted for differences in baseline patient characteristics revealed that the LDA and remission rates by MTX dose in biologic-naïve patients were in the order group 1\group 2\group 3 = group 4 = group 5 (LDA, p = 0.0440; remission, p = 0.0422). In the 1101 biologic-exposed patients, in contrast, LDA rates were 15.5, 20.0, 24.9, 24.4, and 39.5% in groups 1 through 5, respectively (Fig. 1A, right) , and remission rates were 4.8, 9.1, 10.6, 12.5, and 13.7%, respectively (Fig. 1B, right) . The contrast test also revealed that LDA and remission rates by MTX dose in biologic-exposed patients were in the order group 1\group 2\group 3\group 4\group 5 (LDA, p = 0.0009; remission, p = 0.0143).
With respect to safety evaluation of the 5494 patients receiving ADA and MTX, neither serious ADRs nor serious infections differed significantly across the five groups. The incidence of ADRs was significantly higher in group 1 than in the other groups. The incidence of infections was significantly higher in group 5 than in groups 2, 3, and 4 ( Table 3 ).
DISCUSSION
The major finding from post hoc analysis of the MELODY study is that in biologic-naïve patients, MTX in combination with ADA increased LDA and remission rates at week 24 up to a MTX dose of 6-\8 mg/week and then plateaued at higher doses, whereas in biologic-treated patients there was a dose-dependent increase up to C10 mg/week of MTX. The dose-response profile in the biologic-naïve patients appears similar to that observed in the CONCERTO trial [11] . In that trial, biologic-naïve patients who received MTX In the safety analysis, despite no differences in serious ADRs or serious infections, the incidence of ADRs and infections differed significantly between lower-and higher-dose MTX groups. The significantly higher incidence of infections in patients of group 5, who received the highest MTX dose in our study, was consistent with findings from the previous safety analysis of the all-case study [6] . That analysis revealed that the use of MTX at [8 mg/ week represents a risk factor for infections, respiratory infections, severe respiratory infections, and pneumonia. In the present analysis, incidences of ADRs and infections were also significantly higher in patients of group 1 who received MTX at the lowest dose range. Patients of group 1 tended to be older, had longer disease duration, and more concomitant diseases, which are factors for higher risk of ADRs and infections. As a post hoc analysis of an observational study, this study had several limitations. Of note, the Japan College of Rheumatology has published its guidelines for the use of MTX in the treatment of RA, including the supplementation with folic acid, and, in the present study, Japanese patients with RA were treated accordingly. First, the dose of MTX could be changed whenever necessary during combination treatment with ADA. Second, although we adjusted the contrast tests for differences in baseline data, baseline characteristics of patients were different among the groups. Third, as outcome measures available for analysis depend on the original all-case survey, no radiologic or functional data were analyzed in this study, and the efficacy of treatment was analyzed only with clinical measures. A direct comparison between our findings with and those in non-Japanese populations could not be made.
To confirm these data in the Japanese population, a randomized clinical study is needed. To date, there is no scientifically sound explanation for the observation that biologic-exposed patients need higher doses of MTX than biologic-naïve patients to achieve LDA and remission. To address this question in a future study, we must measure disease activity more accurately and use a more clinically relevant endpoint.
CONCLUSION
In the treatment of RA, the effects of MTX in combination with ADA on LDA and remission rates showed a different dose-response profile between biologic-naïve and biologic-exposed patients. In biologic-naïve patients, the effects of MTX plateaued at a dose of 6-\8 mg/week, suggesting that 8 mg/week is sufficient for this patient population.
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